Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845513 | 0.91 | CYP11B2 (0.49) | CYP11B2CYP11B1CYP17A1HTR1DCYP19A1 | |
| SCHEMBL6840478 | 0.82 | CYP11B1 (0.51) | CYP11B2CYP11B1CYP17A1CYP19A1KDM4E | |
| SCHEMBL6846202 | 0.81 | HTR1D (0.49) | CYP11B2CYP11B1CYP17A1HTR1DCYP19A1 | |
| SCHEMBL6846150 | 0.78 | HTR1D (0.55) | CYP11B2CYP11B1CYP17A1HTR1DCYP19A1 | |
| SCHEMBL6658742 | 0.78 | CYP11B2 (0.57) | CYP11B2CYP11B1CYP17A1HTR1DCYP19A1 | |
| SCHEMBL6846114 | 0.74 | HTR1D (0.48) | CYP11B2CYP11B1CYP17A1HTR1DCYP19A1 | |
| SCHEMBL30097476 | 0.73 | BIRC5 (0.43) | KDM4EPTK2 | |
| SCHEMBL699112 | 0.73 | BIRC5 (0.43) | KDM4EPTK2 | |
| SCHEMBL6655307 | 0.73 | CYP11B1 (0.52) | CYP11B2CYP11B1CYP17A1CYP19A1KDM4E | |
| SCHEMBL6659873 | 0.72 | CYP11B2 (0.52) | CYP11B2CYP11B1CYP17A1HTR1DCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | CYP11B2 53/4885CYP11B1 30/4885CYP17A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.